The FDA has announced another voluntary recall of extended-release (ER) metformin, a common medication for treating type 2 diabetes, due to the detection of unacceptable levels of N-nitrosodimethylamine (NDMA).
Kansas City, Missouri-based Nostrum Laboratories is recalling two lots of ER metformin tablets that had been distributed to wholesalers throughout the United States. The lot numbers are MET200101 and MET200301.
Nostrum Laboratories has made plans to notify all affected distributors by letter, and arrangements are being made for the return of all recalled tablets.
“Consumers should consult a healthcare professional to obtain a replacement or a different treatment option,” according to the official announcement. “It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their healthcare professional. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking this drug product.”
